(4-(4-Ethylpiperazin-1-yl)phenyl)boronic acid monohydrochloride

Catalog No.: 
ACLGRF014
CAS No.: 
2096339-70-5
Molecular Formula: 
C12H20BClN2O2
Molecular Weight: 
270.57
(4-(4-Ethylpiperazin-1-yl)phenyl)boronic acid monohydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$149.00InquiryInquiry
250mg95%$298.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(4-(4-Ethylpiperazin-1-yl)phenyl)boronic acid monohydrochloride
IUPAC Name(4-(4-ethylpiperazin-1-yl)phenyl)boronic acid hydrochloride
Molecular FormulaC12H20BClN2O2
Molecular Weight270.57
SMILESCCN1CCN(C2=CC=C(B(O)O)C=C2)CC1.[H]Cl
InChI KeySOCFZGNCUXOEJJ-UHFFFAOYSA-N
SynonymSOCFZGNCUXOEJJ-UHFFFAOYSA-N
CAS No.2096339-70-5

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACLGRF014 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACXOMS609 route compound structure diagram
    ACXOMS609513246-99-6In Stock
  4. Then
  5. ACLGRF014 route product structure diagram
    ACLGRF0142096339-70-5
Inquiry

2. ACLGRF014 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACUXPT746 route compound structure diagram
    ACUXPT7461765-93-1In Stock
  4. Then
  5. ACLGRF014 route product structure diagram
    ACLGRF0142096339-70-5
Inquiry

3. ACLGRF014 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACEGJX062 route compound structure diagram
    ACEGJX0625467-74-3In Stock
  4. Then
  5. ACLGRF014 route product structure diagram
    ACLGRF0142096339-70-5
Inquiry

Comments (0)